Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F20%3AN0000031" target="_blank" >RIV/00064190:_____/20:N0000031 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s10557-020-07095-6" target="_blank" >http://dx.doi.org/10.1007/s10557-020-07095-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10557-020-07095-6" target="_blank" >10.1007/s10557-020-07095-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry

Popis výsledku v původním jazyce

Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.

Název v anglickém jazyce

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry

Popis výsledku anglicky

Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV17-29520A" target="_blank" >NV17-29520A: Dlouhodobé trendy sekundární prevence ICHS a predikce rizika ve vybraném vzorku české populace - česká část studie EURASPIRE V</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CARDIOVASCULAR DRUGS AND THERAPY

ISSN

0920-3206

e-ISSN

1573-7241

Svazek periodika

35

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

801-808

Kód UT WoS článku

000579030000001

EID výsledku v databázi Scopus

2-s2.0-85092791964